MedTrace Logo

Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia

NCT00683618 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 934

Last updated 2012-03-21

Study results available
· View outcomes & findings →

Summary

This trial is to compare the efficacy, safety and tolerability of Rosuvastatin with Atorvastatin by assessing the change of LDL-C in patients with hypercholesterolemia and history of coronary heart disease (CHD) or risk equivalent, or a 10 year CHD risk of no less than 10%, following 6-week treatment and a possible 6 week extension treatment.

Conditions

Interventions

DRUG

Rosuvastatin

Capsule/Tablet, oral, qd, 6 or 12 weeks

DRUG

Atorvastatin

Capsule/Tablet, 10mg, oral, qd, 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Marie Eckerd · AZ Pharmaceuticals - US

  • Zhao Shuiping · 2nd hospital of Xiangya medical university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683618 on ClinicalTrials.gov